Tag: Targeted therapy

More than 160 monoclonal antibodies and related therapeutics were approved by the FDA as of mid-2024, a number that continues to grow rapidly. This reflects the increasing role of these highly specific biologic drugs in modern medicine, with the answer to the question, 'How many FDA approved monoclonal antibodies are there?' constantly evolving as new treatments reach the market.

More than 21 antibody therapeutics were granted a first approval in at least one country during 2024 [1.2.3]. So, **what is the new monoclonal antibody drug?** These lab-made proteins are revolutionizing treatment for cancer, autoimmune disorders, and infectious diseases by targeting specific cells [1.8.1, 1.8.4].

An estimated 3% to 5% of non-small cell lung cancer (NSCLC) cases are driven by an abnormal ALK gene. For this specific patient population, targeted therapies provide a range of FDA approved ALK inhibitor options, which have revolutionized treatment outcomes.

While once considered the fastest method for emergency drug delivery, the **intracardiac route** is now primarily reserved for highly controlled, targeted procedures or is obsolete in human medicine due to its significant risks. Today, understanding the specific advantages of the intracardiac route is essential for appreciating the evolution of modern pharmacology, research, and highly specialized interventional cardiology procedures.

In 2017, the FDA approved the first biologic medication for atopic dermatitis, marking a significant advancement for patients with moderate-to-severe symptoms. What are biologics for eczema? These advanced, injectable drugs offer a new approach by targeting specific immune pathways responsible for the inflammation and itch.

Monoclonal antibodies (mAbs) are a cornerstone of modern medicine, with dozens of approved therapies available to treat a wide array of conditions, from autoimmune diseases to various cancers. At a functional level, these specialized, lab-made proteins are most often categorized into three main groups, which helps clarify what are the three monoclonal antibodies in a therapeutic context.

The global monoclonal antibody therapeutics market was valued at over USD 233 billion in 2024 and is projected to grow significantly [1.11.1]. This highlights the pivotal role of these engineered proteins in modern medicine. So, **what is an example of a monoclonal antibody being used?**

Myelofibrosis is a complex bone marrow cancer characterized by overactive Janus kinase (JAK) signaling, which leads to the formation of scar tissue. Jakafi is a targeted therapy designed to address this underlying mechanism by inhibiting key JAK proteins.

Immunotoxins are highly potent targeted therapeutic agents that combine a targeting ligand with a bacterial toxin to kill cancer cells. While several have received FDA approval, their market availability and status have evolved over time due to manufacturing issues or commercial decisions.

In 2024, biologics, including a high number of monoclonal antibodies, represented 32% of all new drugs approved by the FDA [1.7.1]. So, what drugs are considered monoclonal antibodies, and how do these advanced therapies work to combat complex diseases?